Physician profile
David Eugene Bacha
NPI 1366448482
$179,263.49
in general payments reported to CMS, 2019-2025
41 companies · $38K in 2025
The $38K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $18K · 2021: $19K · 2022: $7,644 · 2023: $22K · 2024: $29K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Food and Beverage: $13K · Consulting Fee: $13K · Travel and Lodging: $12K · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,420.25 |
| Food and Beverage | $12,947.15 |
| Consulting Fee | $12,835.00 |
| Travel and Lodging | $11,781.01 |
| Education | $147.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $110,772.24 | 2019-2025 | Evenity, Prolia, Enbrel |
| Ucb, INC. | $21,754.56 | 2019-2025 | Bimzelx, Cimzia |
| Genentech USA, INC. | $20,305.01 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Janssen Biotech, INC. | $6,187.84 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $4,233.59 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $3,260.89 | 2019-2025 | |
| Horizon Therapeutics Plc | $3,124.17 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $1,430.61 | 2023-2025 | Idacio |
| Novartis Pharmaceuticals Corporation | $1,213.19 | 2019-2025 | |
| Lilly USA, LLC | $1,113.72 | 2019-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $1,045.46 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $917.63 | 2019-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $612.10 | 2021-2024 | Lupkynis |
| Astrazeneca Pharmaceuticals Lp | $549.94 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $546.78 | 2019-2025 | Tymlos |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bacha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.